Risk factors and outcomes for carbapenem-resistant Klebsiella pneumoniae isolation, stratified by its multilocus sequence typing: ST258 versus non-ST258

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Dhar, Sorabh ^a   Martin, Emily T ^b   Lephart, Paul R ^c   McRoberts, John P ^b   Chopra, Teena ^a   Burger, Timothy T ^c   Tal Jasper, Ruthy ^d   Hayakawa, Kayoko ^a   Ofer Friedman, Hadas ^e   Lazarovitch, Tsilia ^e   Zaidenstein, Ronit ^e   Perez, Federico ^f   Bonomo, Robert A ^f,g   Kaye, Keith S ^a   Marchaim, Dror ^d,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e ASSAF HAROFEH MEDICAL CENTER   (Israel)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CRE; KPC; MDRO; Outcome; Risk factors

Indexed keywords

CEPHALOSPORIN; COLISTIN; ERTAPENEM; TIGECYCLINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CONTROLLED STUDY; FEMALE; HUMAN; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 85000763547     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv213     Document Type: Article

References (33)

1. Cuzon G, Naas T, Truong H, et al. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis 2010; 16:1349-56.
2. Kitchel B, Rasheed JK, Endimiani A, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54:4201-7.
3. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848-55.
4. Centers for Disease and Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256-60.
5. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440-58.
6. Moellering RC Jr. NDM-1-a cause for worldwide concern. N Engl J Med 2010; 363:2377-9.
7. Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010; 13:558-64.
8. Lascols C, Peirano G, Hackel M, et al. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA- 48-like enzymes in North America. Antimicrob Agents Chemother 2013; 57:130-6.
9. Pollett S, Miller S, Hindler J, et al. Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013. J Clin Microbiol 2014; 52:4003-9.
10. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355-62.
11. Jones RN, Flonta M, Gurler N, et al. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 2014; 78:429-36.
12. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12:223-30.
13. Endimiani A, Perez F, Bajaksouzian S, et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol 2010; 48:4417-25.
14. Adler A, Paikin S, Sterlin Y, et al. A swordless knight: epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 Klebsiella pneumoniae clone. J Clin Microbiol 2012; 50:3180-5.
15. Lee CH, Chu C, Liu JW, et al. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother 2007; 60:410-3.
16. Grobner S, Linke D, Schutz W, et al. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany. J Med Microbiol 2009; 58:912-22.
17. CLSI. Performance Standards for Antimibrobial Susceptibility Testing. CLSI document M100-S19. Wayne, PA; Clinical and Laboratory Standards Institute; 2009.
18. Jeremiah SS, Balaji V, Anandan S, Sahni RD. A possible alternative to the error prone modified Hodge test to correctly identify the carbapenemase producing Gram-negative bacteria. Indian J Med Microbiol 2014; 32:414-8.
19. Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817-30.
20. Marchaim D, Chopra T, Perez F, et al. Outcomes and genetic relatedness of carbapenem- resistant Enterobacteriaceae at Detroit Medical Center. Infect Control Hosp Epidemiol 2011; 32:861-71.
21. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
22. Endimiani A, Depasquale JM, Forero S, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009; 64:1102-10.
23. Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009; 63:427-37.
24. Diancourt L, Passet V, Verhoef J, et al. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 2005; 43:4178-82.
25. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014; 58:4035-41.
26. Deleo FR, Chen L, Porcella SF, et al. Molecular dissection of the evolution of carbapenem- resistant multilocus sequence type 258 Klebsiella pneumoniae. ProcNatl Acad Sci U S A 2014; 111:4988-93.
27. Chen L, Mathema B, Pitout JD, et al. Epidemic Klebsiella pneumoniae ST258 is a hybrid strain. MBio 2014; 5:e01355-14.
28. Wright MS, Perez F, Brinkac L, et al. Population structure of KPC-producing Klebsiella pneumoniae isolates from midwestern U.S. hospitals. Antimicrob Agents Chemother 2014; 58:4961-5.
29. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem- resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593-9.
30. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96.
31. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185:914-9.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
33. Bion JF, Edlin SA, Ramsay G, et al. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J (Clin Res Ed) 1985; 291:432-4.